Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2003
Revised Date: 
September 2017
  • Life threatening ventricular arrhythmias
  • PO
  • PO:
    • Dosing by Body Surface Area:
      • 100 - 500 mg/m2/day divided BID or TID


Formula for Body Surface Area (BSA):

Click here for BSA Formula



Side Effects: 
  • CVS: hypotension with rapid administration, bradycardia, arrhythmia
  • GI: GI distress, vomiting
  • Hepatic: elevated liver enzymes
Parameters to Monitor: 
  • BP, HR
  • QRS duration and PR interval
  • May increase serum digoxin levels. Reduce digoxin dose by 50% when initiating concurrent propafenone therapy






** Propafenone injection normally acquired through Health Canada's Special Access Program is no longer available as the manufacturer has ceased production.  According to Health Canada there is no alternate supplier. (September 2017) **


-Klasko RK (ed): Drugdexâ System. Thomson MicroMedex, Greenwood Village, Colorado (Vol 123, exp March 2005)

Paul T, Janousek J.  New Antiarrhythmic Drugs in Pediatric Use: Propafenone. Pediatr Cardiol 15: 190-197, 1994

-Reimer A, Paul T, Kalfelz H-C.  Efficacy and Safety of Intravenous and Oral Propafenone in Pediatric Cardiac Dysrhythmias.  Am J Cardiol 1991;68:741-744

- Garson A, Moak JP, Smith RT, Norton JB. Usefulness of Intravenous Propafenone for Control of Postoperative Junctional Ectopic Tachycardia.  Am J Cardiol 1987; 59: 1422-1424


The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.